teee_nt10k.htm

	UNITED STATES	OMB APPROVAL
	SECURITIES AND EXCHANGE COMMISSION	OMB Number . . . . 3235-0058
	Washington, D.C.20549	Expires: . . . . . . . August 31, 2015
		Estimated average burden
	FORM 12b-25	hours per response . . . . . . . . 2.50

	NOTIFICATION OF LATE FILING

(Check one):	o Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR	SEC FILE NUMBER
		0000319016
	For Period Ended: _______________________________________________
		CUSIP NUMBER
	x Transition Report on Form 10-K	36113u101
	o Transition Report on Form 20-F
	o Transition Report on Form 11-K
	o Transition Report on Form 10-Q
	o Transition Report on Form N-SAR

	For the transition period ended: December 31, 2013

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _______________________________

PART I - REGISTRANT INFORMATION

Fuse Medical, Inc.

Full Name of Registrant

Former Name if Applicable

4770 Bryant Irvin Court, Suite 300

Address of Principal Executive Office (Street and Number)

Fort Worth, TX 76107

City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
x	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report, or portion thereof, could not be filed within the prescribed time period.

The Registrant’s Transition Report on Form 10-K for the period ended December 31, 2013 cannot be filed within the prescribed time period because the Registrant is unable to complete the presentation of its financial statements and the analysis thereof without unreasonable effort and expense, due in part to a “reverse merger” transaction consummated on May 28, 2014, as more fully described in the Registrant’s Current Reports on Form 8-K filed on May 29, 2014, Form 8-K/A filed on May 30, 2014, and Form 8-K/A filed on August 6, 2014.

PART IV - OTHER INFORMATION

(1)	Name and telephone number of person to contact in regard to this notification

D. Alan Meeker		817		439-7025
(Name)		(Area code)		(Telephone Number)

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). x Yes o No

(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? x Yes o No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

As a result of the “reverse merger” referenced above, the acquired company is now the reporting company. Therefore, the results of operations will be those of the acquired company and will differ significantly from the results reported for the corresponding period for the last fiscal year. A reasonable estimate of the results cannot be made.

Fuse Medical, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 26, 2014	By:	/s/ D. Alan Meeker
		D. Alan Meeker Chief Executive Officer